KRAS and neoplasm: Several neoantigens of this kind have been discovered very recently (e.g., the ones derived from KRAS G12D [123,136] or p53 hot spot mutations [125,139,140]), raising the possibility of generating “off-the-shelf ” TCR-engineered T cell products for MHC-matched patients with tumours expressing these neoantigens.